“LimFlow recently presented compelling 12-month data from its PROMISE I US feasibility study at the VIVA conference, which demonstrated amputation free survival of 70%, limb salvage of 77%, and survival of 91% at 12 months,” explains LimFlow CEO Dan Rose. … Read More